A Phase 3 interventional study of Inebilizumab and Placebo in IgG4 Related Disease, sponsored by Amgen. Active, not recruiting at 72 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-11.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Immunoglobulin G4-Related Disease with a site in China — 25 open to participants now, 28 under way, 5 of them phase 3. Immunoglobulin G4-Related Disease · China.
Among the 40 studies in Immunoglobulin G4-Related Disease with a site in China, this one is the 5th largest by enrollment of the 36 interventional ones that give a count, is one of 3 that started in 2020, is one of 4 in phase 3, reaches primary completion later than 0 of the 27 other live ones, and was the 10th registered.
72 studies on the registry are indexed under Immunoglobulin G4-Related Disease; 40 are open to participants now.
Browse Immunoglobulin G4-Related Disease studies →25 of the 40 studies in Immunoglobulin G4-Related Disease with a site in China are open now. Recruiting first, the newest first:
Amgen · Sites in China, United States, Brazil and 5 more countries
Ages 2–18
Acepodia Biotech, Inc. · Sites in China, United States, Japan
Ages 18+
Sanofi · Sites in China, United States, Argentina and 16 more countries
Ages 18+
Chinese PLA General Hospital · Sites in China
Ages 18–75
Peking Union Medical College Hospital · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 28 Immunoglobulin G4-Related Disease studies recruiting now, 12 (43%) set no upper age limit and 13 (46%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 8 · Phase 3 6 · Phase 4 3
First in 2012; this study’s year is marked. 3 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 135 is above the median of 48 across 52 interventional studies indexed under Immunoglobulin G4-Related Disease.
Median enrollment 59 across the 36 interventional studies, 780 across the 4 observational. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 40 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Amgen has 2 studies filed under Immunoglobulin G4-Related Disease — fewer than ten, so there is no comparison to draw.
7 of the studies in Immunoglobulin G4-Related Disease with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03023371Peking Union Medical College HospitalNational Registry of IgG4-RD in China | 2026-12 |
| NCT06285279Nanjing University School of MedicineThe BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases | 2026-12-31 |
| NCT06978738Changzhou No.2 People's HospitalUCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases | 2027-05 |
| NCT06978647China Immunotech (Beijing) Biotechnology Co., Ltd.A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases | 2027-05-19 |
| NCT06497387Tongji HospitalSafety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related Disease | 2027-07 |
Add all 7 to your calendar (.ics) → With an account.
Among the 40 studies in Immunoglobulin G4-Related Disease with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate the efficacy and safety of inebilizumab for the prevention of flare of Immunoglobulin G4-related disease (IgG4-RD).
After a screening period of up to 28 days, subjects with IgG4-RD at high risk of flare due to multi-organ disease and recent active disease will be randomized in a 1:1 ratio to receive intravenous (IV) inebilizumab or placebo after premedication during the 52-week randomized control period (RCP). All subjects will receive an initial tapering dose of glucocorticoids (GCs) to complete treatment of their active disease. Flares occurring during study will be treated. The primary endpoint is time to a first adjudication committee-determined, investigator-treated disease flare during the RCP. The primary analysis will be conducted when the last subject completes the RCP visit or discontinues the RCP. This study includes an optional 3-year open-label treatment period. The study also includes a Safety Follow-up Period (SFUP) of up to 730 days for all participants. The expected duration of each subject's participation in this study is up to 400 days (screening and RCP), plus up to 1095 days for eligible subjects who enroll in the optional open label period (OLP), and up to 730 days for the SFUP, for a total maximum duration of up to 2273 days (screening, RCP, interval between RCP and OLP, OLP, and FSUP).
Study acquired from Horizon in 2024.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Inebilizumab administered as an IV infusion.
Drug: Inebilizumab
Placebo administered as an IV infusion.
Other: Placebo
Inebilizumab is a monoclonal antibody that depletes B cells.
Placebo
RCP: Time to Disease Flare
Time to disease flare was defined as the number of days from Day 1 (dosing) to the date of the first treated and Adjudication Committee (AC)-determined IgG4-RD flare within the 52-week RCP. The date of disease flare was determined by the initiation of any flare treatment, including new or increased glucocorticoid (GC) treatment, other immunotherapy, or an interventional procedure, as deemed necessary by the Investigator to address the flare. Kaplan-Meier (KM) method was used to estimate the median time to flare, and 95% confidence interval (CI).
Time frame: Up to Week 52
RCP: Annualized Rate of Treated and AC-Determined Flares During the RCP
The annualized rate of treated and AC-determined flares during the 52-week RCP was calculated by dividing the total number of treated and AC-determined flares by the total time at risk (in years) for all participants. This measure reflected the frequency of disease flares per person per year during the RCP.
Time frame: Week 52
RCP: Percentage of Participants Achieving Flare-free, Treatment-free Complete Remission at Week 52
Flare-free, treatment-free complete remission at Week 52 was defined as the absence of evident disease activity at Week 52, no AC-determined flare during the RCP, and no treatment for flare or disease control, except for the required 8-week glucocorticoid taper. Lack of evident disease activity was determined by either a score of 0 on the IgG4-RD Responder Index (score range: 0-4, with lower scores indicating better disease control) or an investigator's assessment that no disease activity was present based on physical, laboratory, pathology, or other evidence.
Time frame: Week 52
RCP: Percentage of Participants Achieving Flare-free, Corticosteroid-free Complete Remission at Week 52
Flare-free, corticosteroid-free complete remission at Week 52 was defined as the absence of evident disease activity at Week 52, no AC-determined flare during the RCP, and no corticosteroid treatment for flare or disease control, except for the required 8-week glucocorticoid taper. Lack of evident disease activity was determined by either a score of 0 on the IgG4-RD Responder Index (score range: 0-4, with lower scores indicating better disease control) or an investigator's assessment that no disease activity was present based on physical, laboratory, pathology, or other evidence.
Time frame: Week 52
Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs) During the RCP
An adverse event (AE) referred to any untoward medical occurrence in a clinical study participant, regardless of a causal relationship with the study treatment. TEAEs included any event occurring after the participant received the study treatment. Clinically significant changes in vital signs, electrocardiograms, and laboratory tests recorded after treatment administration were documented as TEAEs. Serious AEs (SAEs) were untoward medical occurrences after the first dose, irrespective of a causal link to the study treatment, that led to death, were life-threatening, required hospitalization or its prolongation, caused significant disability, resulted in congenital anomalies, or were considered other medically important events. AEs were graded (Grade 3: severe; Grade 4: life-threatening; Grade 5: death) using the Common Terminology Criteria for Adverse Events \[CTCAE\]).
Time frame: Up to Week 52
Number of Participants Who Experienced TEAEs During the OLP
An AE referred to any untoward medical occurrence in a clinical study participant, regardless of a causal relationship with the study treatment. TEAEs included any event occurring after the participant received the study treatment. Clinically significant changes in vital signs, electrocardiograms, and laboratory tests recorded after treatment administration were documented as TEAEs. SAEs were untoward medical occurrences after the first dose, irrespective of a causal link to the study treatment, that led to death, were life-threatening, required hospitalization or its prolongation, caused significant disability, resulted in congenital anomalies, or were considered other medically important events. AEs were graded (Grade 3: severe; Grade 4: life-threatening; Grade 5: death) using the CTCAE).
Time frame: From the first dose of investigational product in OLP to the end of OLP or cutoff date; median (min, max) duration was 51.6 (0.1, 108.3) weeks.
RCP: Number of Participants With Anti-drug Antibodies (ADA) to Inebilizumab by Week 52
Incidence was the proportion of the participants with ADA positive post-baseline only or boosted their preexisting ADA (at least 4-fold over the baseline titer) during the study period. Baseline was defined as the last valid value on or before the first dose of RCP.
Time frame: Baseline to Week 52
RCP: Time to Initiation of First Treatment for New or Worsening Disease Activity Within the RCP
Time to initiation of the first treatment (medication or procedure) for new or worsening disease activity, as determined by the investigator, within the RCP, was measured from day 1 (dosing) to the date the first treatment was administered. It Included any treatment initiated by the investigator for disease activity, regardless of the AC determination of flare. KM method was used to estimate the median time to the initiation of first treatment or worsening of disease activity, and 95% CI.
Time frame: Week 52
RCP: Annualized Flare Rate for AC-Determined IgG4-RD Flares at Week 52
The annualized flare rate for AC-determined IgG4-RD flares, whether or not treated, during the RCP was calculated by dividing the total number of AC-determined flares by the total time at risk (in years) for all participants. This measure reflected the frequency of IgG4-RD flares, irrespective of treatment, per participant per year during the study period.
Time frame: Week 52
RCP: Cumulative Glucocorticoid (GC) Use for IgG4-RD Disease Control by Week 52
GC use was calculated as the cumulative glucocorticoid dose (in milligrams) taken for the purpose of IgG4-RD disease control during the RCP. This measure accounted for all GC treatments administered to participants to manage disease activity throughout the study period.
Time frame: Week 52
Participants affected by immunoglobulin G4-related disease (IgG4-RD) were recruited across 46 sites in Argentina, Australia, Canada, China, France, Germany, Israel, Italy, Japan, Mexico, Netherlands, Poland, Spain, Turkey, the United Kingdom and the United States, between December 2020 and February 2024 which was the safety data cutoff date.
| Milestone | RCP: Placebo/OLP: Inebilizumab 300 mg | RCP: Inebilizumab 300 mg/OLP: Inebilizumab 300 mg |
|---|---|---|
| Started | 67 | 68 |
| Started optional olp | 49 | 53 |
| Completed | 63 | 64 |
| Not completed | 4 | 4 |
| Withdrew: Adverse event | 0 | 2 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Withdrew: Miscellaneous | 2 | 1 |
Time to disease flare was defined as the number of days from Day 1 (dosing) to the date of the first treated and Adjudication Committee (AC)-determined IgG4-RD flare within the 52-week RCP. The date of disease flare was determined by the initiation of any flare treatment, including new or increased glucocorticoid (GC) treatment, other immunotherapy, or an interventional procedure, as deemed necessary by the Investigator to address the flare. Kaplan-Meier (KM) method was used to estimate the median time to flare, and 95% confidence interval (CI).
| Days | Placebo | Inebilizumab 300 mg |
|---|---|---|
| RCP: Time to Disease Flare | 246.0 (191.0 to NA) | NA (371.0 to NA) |
The annualized rate of treated and AC-determined flares during the 52-week RCP was calculated by dividing the total number of treated and AC-determined flares by the total time at risk (in years) for all participants. This measure reflected the frequency of disease flares per person per year during the RCP.
| Flares per person per year | Placebo | Inebilizumab 300 mg |
|---|---|---|
| RCP: Annualized Rate of Treated and AC-Determined Flares During the RCP | 0.71 (0.53 to 0.94) | 0.10 (0.05 to 0.21) |
Flare-free, treatment-free complete remission at Week 52 was defined as the absence of evident disease activity at Week 52, no AC-determined flare during the RCP, and no treatment for flare or disease control, except for the required 8-week glucocorticoid taper. Lack of evident disease activity was determined by either a score of 0 on the IgG4-RD Responder Index (score range: 0-4, with lower scores indicating better disease control) or an investigator's assessment that no disease activity was present based on physical, laboratory, pathology, or other evidence.
| Participants | Placebo | Inebilizumab 300 mg |
|---|---|---|
| RCP: Percentage of Participants Achieving Flare-free, Treatment-free Complete Remission at Week 52 | 15 | 39 |
Flare-free, corticosteroid-free complete remission at Week 52 was defined as the absence of evident disease activity at Week 52, no AC-determined flare during the RCP, and no corticosteroid treatment for flare or disease control, except for the required 8-week glucocorticoid taper. Lack of evident disease activity was determined by either a score of 0 on the IgG4-RD Responder Index (score range: 0-4, with lower scores indicating better disease control) or an investigator's assessment that no disease activity was present based on physical, laboratory, pathology, or other evidence.
| Participants | Placebo | Inebilizumab 300 mg |
|---|---|---|
| RCP: Percentage of Participants Achieving Flare-free, Corticosteroid-free Complete Remission at Week 52 | 15 | 40 |
An adverse event (AE) referred to any untoward medical occurrence in a clinical study participant, regardless of a causal relationship with the study treatment. TEAEs included any event occurring after the participant received the study treatment. Clinically significant changes in vital signs, electrocardiograms, and laboratory tests recorded after treatment administration were documented as TEAEs. Serious AEs (SAEs) were untoward medical occurrences after the first dose, irrespective of a causal link to the study treatment, that led to death, were life-threatening, required hospitalization or its prolongation, caused significant disability, resulted in congenital anomalies, or were considered other medically important events. AEs were graded (Grade 3: severe; Grade 4: life-threatening; Grade 5: death) using the Common Terminology Criteria for Adverse Events \[CTCAE\]).
| Participants | Placebo | Inebilizumab 300 mg |
|---|---|---|
| TEAEs | 66 | 66 |
| SAEs | 6 | 12 |
| Fatal TEAEs | 0 | 0 |
| Grade ≥ 3 TEAEs | 8 | 12 |
An AE referred to any untoward medical occurrence in a clinical study participant, regardless of a causal relationship with the study treatment. TEAEs included any event occurring after the participant received the study treatment. Clinically significant changes in vital signs, electrocardiograms, and laboratory tests recorded after treatment administration were documented as TEAEs. SAEs were untoward medical occurrences after the first dose, irrespective of a causal link to the study treatment, that led to death, were life-threatening, required hospitalization or its prolongation, caused significant disability, resulted in congenital anomalies, or were considered other medically important events. AEs were graded (Grade 3: severe; Grade 4: life-threatening; Grade 5: death) using the CTCAE).
Results for this outcome have not been posted.
Incidence was the proportion of the participants with ADA positive post-baseline only or boosted their preexisting ADA (at least 4-fold over the baseline titer) during the study period. Baseline was defined as the last valid value on or before the first dose of RCP.
| Participants | Placebo | Inebilizumab 300 mg |
|---|---|---|
| RCP: Number of Participants With Anti-drug Antibodies (ADA) to Inebilizumab by Week 52 | 5 | 6 |
Time to initiation of the first treatment (medication or procedure) for new or worsening disease activity, as determined by the investigator, within the RCP, was measured from day 1 (dosing) to the date the first treatment was administered. It Included any treatment initiated by the investigator for disease activity, regardless of the AC determination of flare. KM method was used to estimate the median time to the initiation of first treatment or worsening of disease activity, and 95% CI.
| Days | Placebo | Inebilizumab 300 mg |
|---|---|---|
| RCP: Time to Initiation of First Treatment for New or Worsening Disease Activity Within the RCP | 237.0 (143.0 to 310.0) | NA (371.0 to NA) |
The annualized flare rate for AC-determined IgG4-RD flares, whether or not treated, during the RCP was calculated by dividing the total number of AC-determined flares by the total time at risk (in years) for all participants. This measure reflected the frequency of IgG4-RD flares, irrespective of treatment, per participant per year during the study period.
| Flares per participant per year | Placebo | Inebilizumab 300 mg |
|---|---|---|
| RCP: Annualized Flare Rate for AC-Determined IgG4-RD Flares at Week 52 | 0.75 (0.57 to 0.99) | 0.16 (0.09 to 0.29) |
GC use was calculated as the cumulative glucocorticoid dose (in milligrams) taken for the purpose of IgG4-RD disease control during the RCP. This measure accounted for all GC treatments administered to participants to manage disease activity throughout the study period.
| mg | Placebo | Inebilizumab 300 mg |
|---|---|---|
| RCP: Cumulative Glucocorticoid (GC) Use for IgG4-RD Disease Control by Week 52 | 1384.53 ± 1723.26 | 118.25 ± 438.97 |
Collected over For RCP mortality reporting: from randomization to the end of RCP; median (min, max) was 54.1 (2.1, 65.1) weeks. For RCP AE reporting: from Day 1 to the end of RCP or cutoff date; median (min, max) was 54.1 (2.1, 65.1) weeks. For OLP mortality and AE reporting: from the 1st dose of IP in OLP to the end of OLP or cutoff date; median (min, max) was 51.6 (0.1, 108.3) weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| RCP: Placebo | 0/67 (0%) | 6/67 (9%) | 49/67 (73.1%) |
| RCP: Inebilizumab 300 mg | 0/68 (0%) | 12/68 (17.6%) | 54/68 (79.4%) |
| OLP: Inebilizumab 300 mg | 0/90 (0%) | 14/90 (15.6%) | 51/90 (56.7%) |
| Event | RCP: Placebo | RCP: Inebilizumab 300 mg | OLP: Inebilizumab 300 mg |
|---|---|---|---|
| PneumoniaInfections and infestations | 0/67 | 0/68 | 2/90 |
| Coronary artery stenosisCardiac disorders | 1/67 | 0/68 | 0/90 |
| Hepatic function abnormalHepatobiliary disorders | 1/67 | 0/68 | 0/90 |
| Diabetes mellitusMetabolism and nutrition disorders | 1/67 | 0/68 | 1/90 |
| Acute kidney injuryRenal and urinary disorders | 1/67 | 0/68 | 0/90 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 1/67 | 0/68 | 0/90 |
| Sinus disorderRespiratory, thoracic and mediastinal disorders | 1/67 | 0/68 | 0/90 |
| Anaphylactic reactionImmune system disorders | 0/67 | 1/68 | 0/90 |
| AppendicitisInfections and infestations | 0/67 | 1/68 | 0/90 |
| COVID-19Infections and infestations | 0/67 | 1/68 | 0/90 |
| Event | RCP: Placebo | RCP: Inebilizumab 300 mg | OLP: Inebilizumab 300 mg |
|---|---|---|---|
| COVID-19Infections and infestations | 13/67 | 15/68 | 19/90 |
| LymphopeniaBlood and lymphatic system disorders | 6/67 | 11/68 | 1/90 |
| DiarrhoeaGastrointestinal disorders | 9/67 | 3/68 | 2/90 |
| AstheniaGeneral disorders | 8/67 | 2/68 | 1/90 |
| Upper respiratory tract infectionInfections and infestations | 8/67 | 4/68 | 10/90 |
| Urinary tract infectionInfections and infestations | 4/67 | 8/68 | 3/90 |
| Abdominal painGastrointestinal disorders | 7/67 | 4/68 | 3/90 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 7/67 | 4/68 | 3/90 |
| HeadacheNervous system disorders | 7/67 | 6/68 | 3/90 |
| PruritusSkin and subcutaneous tissue disorders | 6/67 | 3/68 | 1/90 |
Full Analysis Set: all participants who received any dose of investigational product during the RCP.
| Age, Continuous(Years) | Placebo | Inebilizumab 300 mg | Total |
|---|---|---|---|
| Mean | 58.2 ± 12.2 | 58.2 ± 11.5 | 58.2 ± 11.8 |
| Sex: Female, Male(Participants) | Placebo | Inebilizumab 300 mg | Total |
|---|---|---|---|
| Female | 18 | 29 | 47 |
| Male | 49 | 39 | 88 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Inebilizumab 300 mg | Total |
|---|---|---|---|
| Hispanic or Latino | 8 | 8 | 16 |
| Not Hispanic or Latino | 53 | 56 | 109 |
| Unknown or Not Reported | 6 | 4 | 10 |
| Race/Ethnicity, Customized(Participants) | Placebo | Inebilizumab 300 mg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 2 | 2 |
| Asian | 25 | 38 | 63 |
| Black or African American | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| White | 32 | 21 | 53 |
| Other | 2 | 2 | 4 |
| Unknown | 1 | 0 | 1 |
| Not Reported | 6 | 4 | 10 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2020 to primary completion in Apr 2024, 40 months.
Results were first posted in Jun 2025, 1 year 2 months after primary completion. A results delay was requested in Mar 2025.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Inebilizumab
Immunoglobulin G4-Related Disease →